| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Immune Response Corporation, Carlsbad, CA 92008
A novel membrane-bound form of GM-CSF (mbGM-CSF) was expressed on the surface of the mouse mastocytoma cell line P815 to target tumor cell-associated Ags to epidermal Langerhans cells. Transfected clones stimulated the proliferation of syngeneic bone marrow cells, indicating that mbGM-CSF is biologically active. We evaluated the in vivo effects of mbGM-CSF by comparing the growth of mbGM-CSF cells (termed 1D6.1E5) to that of wild-type P815 cells in DBA/2 mice. The growth rates of tumors initiated by P815 and 1D6.1E5 were similar until day 12, after which P815 tumors grew to large sizes while 1D6.1E5 tumors were rejected. In contrast, the growth of both tumors was unimpeded when injected into nude mice, suggesting that a T cell-dependent antitumor response was induced by 1D6.1E5 in normal mice. Lymphocytes from 1D6.1E5-vaccinated mice were able to kill 51Cr-labeled P815 cells in a dose-dependent fashion that was inhibited by anti-CD8 Abs, suggesting that the antitumor response involved CD8+ CTL. We then tested whether vaccination with these cells would elicit a protective antitumor response by injecting mice with either irradiated 1D6.1E5 or P815 cells and challenging them with nonirradiated P815 cells. 1D6.1E5-treated mice grew small tumors that soon disappeared in all animals. In contrast, the majority of animals receiving the irradiated wild-type tumor vaccine grew large tumors, and 50% died. These data demonstrate that mbGM-CSF expressed on the surface of tumor cells is biologically active and elicits protective antitumor immunity.
This article has been cited by other articles:
|
|
 |
|
  H. J. Kueng, V. M. Leb, D. Haiderer, G. Raposo, C. Thery, S. V. Derdak, K. G. Schmetterer, A. Neunkirchner, C. Sillaber, B. Seed, et al. General Strategy for Decoration of Enveloped Viruses with Functionally Active Lipid-Modified Cytokines J. Virol., August 15, 2007; 81(16): 8666 - 8676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Dvorkin, X. Song, S. Argov, R. M. White, M. Zoller, S. Segal, C. A. Dinarello, E. Voronov, and R. N. Apte Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1{alpha} J. Leukoc. Biol., July 1, 2006; 80(1): 96 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Song, E. Voronov, T. Dvorkin, E. Fima, E. Cagnano, D. Benharroch, Y. Shendler, O. Bjorkdahl, S. Segal, C. A. Dinarello, et al. Differential Effects of IL-1{alpha} and IL-1{beta} on Tumorigenicity Patterns and Invasiveness J. Immunol., December 15, 2003; 171(12): 6448 - 6456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nagarajan and P. Selvaraj Glycolipid-anchored IL-12 Expressed on Tumor Cell Surface Induces Antitumor Immune Response Cancer Res., May 1, 2002; 62(10): 2869 - 2874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Liau, E. R. Jensen, T. J. Kremen, S. K. Odesa, S. N. Sykes, M. C. Soung, J. F. Miller, and J. M. Bronstein Tumor Immunity within the Central Nervous System Stimulated by Recombinant Listeria monocytogenes Vaccination Cancer Res., April 1, 2002; 62(8): 2287 - 2293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Reali, J. W. Greiner, A. Corti, H. J. Gould, F. Bottazzoli, G. Paganelli, J. Schlom, and A. G. Siccardi IgEs Targeted on Tumor Cells: Therapeutic Activity and Potential in the Design of Tumor Vaccines Cancer Res., July 1, 2001; 61(14): 5517 - 5522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Graf, M. R. Jadus, J. C. Hiserodt, H. T. Wepsic, and G. A. Granger Development of Systemic Immunity to Glioblastoma Multiforme Using Tumor Cells Genetically Engineered to Express the Membrane-Associated Isoform of Macrophage Colony-Stimulating Factor J. Immunol., November 15, 1999; 163(10): 5544 - 5551. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
